Sands Capital Management - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Sands Capital Management ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$648,707
+5.0%
9,530
+26.0%
0.00%0.0%
Q2 2023$617,613
-98.9%
7,566
-99.0%
0.00%
-98.9%
Q1 2023$55,446,193
+90737.3%
747,354
+1.5%
0.18%
-20.8%
Q4 2022$61,039
-99.9%
736,473
+307.5%
0.23%
+19.7%
Q3 2022$51,330,000
-7.0%
180,740
+13.5%
0.19%
+1.0%
Q2 2022$55,201,000
-23.2%
159,247
-4.0%
0.19%
+15.8%
Q1 2022$71,845,000
+42.8%
165,908
+70.7%
0.16%
+77.4%
Q4 2021$50,296,000
+4.7%
97,220
-1.9%
0.09%
+16.2%
Q3 2021$48,047,000
+9.0%
99,153
+1.2%
0.08%
+6.7%
Q2 2021$44,097,000
+32.9%
97,936
+12.7%
0.08%
+17.2%
Q1 2021$33,184,00086,8850.06%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders